Drug use concomitant with cyclosporine immunosuppressive therapy for 3 years after renal transplantation

被引:12
作者
Thamer, M
Chan, JK
Ray, NF
Vassalotti, JA
Kimmel, PL
机构
[1] Med Technol & Practice Patterns Inst, Washington, DC 20007 USA
[2] George Washington Univ, Med Ctr, Div Renal Dis & Hypertens, Washington, DC 20037 USA
关键词
cyclosporine; immunosuppressive therapy; nephrotoxic drugs; medical expenditures; renal transplantation;
D O I
10.1053/ajkd.1998.v31.pm9469499
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Little is known about outpatient drug use concomitant with cyclosporine immunosuppressive therapy following renal transplantation. In part, this stems from the difficulty in monitoring drugs not covered by Medicare. Using several linked state and federal program data bases, a cohort of dually eligible Medicare/Medicaid California residents aged greater than or equal to 18 years with a first cadaver transplant in 1988 was followed for 3 years to examine drug use and medical expenditures: 99, 122, and 90 patients met these inclusion criteria in each study year, respectively. More than one third of the study population received one or more drugs that inhibit metabolism and increase cyclosporine circulating blood levels (class I) in each year posttransplant. The most commonly prescribed were diltiazem, verapamil, metoclopramide, and ketoconazole. Patients receiving class I drugs had a lower mean cyclosporine dose compared with those not receiving such drugs in all three study years, suggesting that overall cost savings were obtained among patients using class I drugs. Less than one tenth of the study population in any given year received a drug that induces metabolism and decreases cyclosporine blood levels (class II), the most common of which was phenytoin. Use of nephrotoxic drugs leg, trimethoprim-sulfamethoxazole, gentamicin, and tobramycin) that exhibit nephrotoxic synergy when used with cyclosporine was common. Almost half of all posttransplant patients were prescribed a nephrotoxic drug during the study period. Pharmaceuticals (primarily cyclosporine) accounted for 35% to 43% of the approximately $17,000 to $19,500 per patient annual health care expenditures incurred in the first 3 years following kidney transplantation. (C) 1998 by the National Kidney Foundation, Inc.
引用
收藏
页码:283 / 292
页数:10
相关论文
共 34 条
[1]  
*AM SOC TRANSPL SU, 1990, SURV PRES STAT REIMB
[2]  
[Anonymous], 1984, J Infect Dis, V150, P372
[3]  
[Anonymous], 1991, Kidney failure and the federal government. Committee for the Study of the Medicare End-Stage Renal Disease Program
[4]  
CALNE RY, 1987, LANCET, V2, P506
[5]   PREVENTION OF INFECTION BY TRIMETHOPRIM-SULFAMETHOXAZOLE PLUS AMPHOTERICIN-B IN PATIENTS WITH ACUTE NONLYMPHOCYTIC LEUKEMIA [J].
DEKKER, AW ;
ROZENBERGARSKA, M ;
SIXMA, JJ ;
VERHOEF, J .
ANNALS OF INTERNAL MEDICINE, 1981, 95 (05) :555-559
[6]  
*EUR MULT TRIAL GR, 1983, LANCET, V2, P986
[7]  
FIRST MR, 1989, LANCET, V2, P1198, DOI 10.1016/S0140-6736(89)91802-3
[8]   Calcium antagonists: Not appropriate as first line antihypertensive agents [J].
Furberg, CD ;
Psaty, BM .
AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (02) :122-125
[9]   SHOULD DIHYDROPYRIDINES BE USED AS FIRST-LINE DRUGS IN THE TREATMENT OF HYPERTENSION - THE CON SIDE [J].
FURBERG, CD ;
PSATY, BM .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (20) :2157-2161
[10]  
Hibbins M, 1993, Transpl Immunol, V1, P66, DOI 10.1016/0966-3274(93)90061-C